On August 11, XTALPI rose 5.6% in regular trading, trading at HKD 8.53/share with turnover of HKD 127 million, extending the previous session's strong performance.

On the news front, the company recently launched its XtalPi Science intelligent platform and co-initiated the \"Scientific Intelligence Open Ecosystem Alliance\" with 26 institutions. Market expectations are rising for a valuation re-rating from a traditional CRO service provider to an AI platform company. Additionally, JP Morgan recently initiated coverage with an \"Overweight\" rating, while Zheshang Securities maintained a \"Buy\" rating, noting that after stripping out a one-time pipeline payment, core business revenue grew 65% year-over-year.

At the sector level, the Life Sciences Tools & Services industry strengthened broadly, with PHARMARON up 2.4%, INSILICO up 1.65%, WUXI APPTEC up 1.62%, GENSCRIPT BIO up 1.24%, and WUXI BIO up 1.21%, reflecting continued capital inflows into the AI-driven drug discovery theme. The company's board meeting scheduled for August 19 to review interim results has also attracted market attention ahead of the earnings window.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)